CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

2011/01/26 by MV Relling, M V Relling, Teri E. Klein +1 · 1,169 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics · #Biology #Clinical Practice #Family medicine #Gene #Genetics #Genomics and Rare Diseases #Genotype #Medicine #Pharmaceutical studies and practices #Pharmacogenetics #Pharmacogenetics and Drug Metabolism #Pharmacogenomics #Pharmacology

paper · open access · doi:10.1038/clpt.2010.279

published in Clinical Pharmacology & Therapeutics 89(3), 464-467 (Wiley)

openalex publication_date 2011/01/26 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Abstract

The slow rate at which pharmacogenetic tests are being adopted in clinical practice is partly due to the lack of specific guidelines on how to adjust medications on the basis of the genetic test results. One of the goals of the Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health's Pharmacogenomics Research Network (http://www.pgrn.org) and the Pharmacogenomics Knowledge Base (PharmGKB, http://www.pharmgkb.org) is to provide peer-reviewed, updated, evidence-based, freely accessible guidelines for gene/drug pairs. These guidelines will facilitate the translation of pharmacogenomic knowledge from bench to bedside. Clinical Pharmacology & Therapeutics (2011) 89 3, 464–467. doi:10.1038/clpt.2010.279

Cited by

• Pharmacogenomics Knowledge for Personalized Medicine
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
• An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
• The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems
• Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method
• Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts
• Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine
• Emerging role of genetics in kidney transplantation
• deCYPher: Star Allele-Resolution Computational Framework of Pharmacogenes for Haplotype-Resolved Long-Read Assemblies
• TypeAssembly: Copy number estimation and allele typing for haplotype assemblies
• Pharmacogenetics and adverse drug reports: Insights from a United Kingdom national pharmacovigilance database
• Pharmacogenomic considerations in opioid analgesia
• Pharmacogenetics in Clinical Practice: How far Have we Come and where are we Going?
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
• DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation
• Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. [europepmc]
• Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. [europepmc]
• Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. [europepmc]
• Pharmacogenomics and individualized medicine: translating science into practice. [europepmc]
• Pharmacogenomics knowledge for personalized medicine. [europepmc]
• Cancer pharmacogenomics: strategies and challenges. [europepmc]
• The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. [europepmc]
• PharmGKB: the Pharmacogenomics Knowledge Base. [europepmc]
• Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. [europepmc]
• Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. [europepmc]
• PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. [europepmc]
• Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. [europepmc]
• Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. [europepmc]
• Pharmacogenomics in the clinic. [europepmc]
• Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. [europepmc]
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. [europepmc]
• Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. [europepmc]
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. [europepmc]
• Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. [europepmc]
• PharmGKB: A worldwide resource for pharmacogenomic information. [europepmc]
• Pharmacogenomics. [europepmc]
• The "All of Us" Research Program. [europepmc]
• PharmVar GeneFocus: CYP2D6. [europepmc]
• The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. [europepmc]
• Pharmacogenetics at Scale: An Analysis of the UK Biobank. [europepmc]

Related

• The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems
• Pharmacogenomics Knowledge for Personalized Medicine
• Pharmacogenomics: a systems approach
• Pharmacogenomics of Adverse Drug Reactions: Practical Applications and Perspectives
• Pharmacogenetics and drug metabolism - from rudiments to current for individualised medicine